Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
- MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
- Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
- Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
- It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.